Daiwa Securities Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$46.8M Buy
335,572
+6,165
+2% +$863K 0.13% 92
2025
Q4
$40.4M Sell
329,407
-45,854
-12% -$5.57M 0.13% 104
2025
Q3
$41.7M Buy
375,261
+12,362
+3% +$1.41M 0.14% 105
2025
Q2
$40.2M Sell
362,899
-4,561
-1% -$485K 0.15% 99
2025
Q1
$41.2M Buy
367,460
+22,677
+7% +$2.34M 0.17% 91
2024
Q4
$31.8M Buy
344,783
+39,700
+13% +$3.57M 0.14% 93
2024
Q3
$25.6M Buy
305,083
+89,992
+42% +$6.87M 0.12% 109
2024
Q2
$14.8M Buy
215,091
+10,703
+5% +$714K 0.08% 151
2024
Q1
$15M Buy
204,388
+23,747
+13% +$1.83M 0.08% 134
2023
Q4
$14.6M Buy
180,641
+10,475
+6% +$815K 0.09% 128
2023
Q3
$12.8M Buy
170,166
+17,492
+11% +$1.35M 0.09% 134
2023
Q2
$11.8M Buy
152,674
+3,150
+2% +$251K 0.08% 139
2023
Q1
$12.4M Buy
149,524
+9,187
+7% +$761K 0.09% 130
2022
Q4
$12M Buy
140,337
+4,055
+3% +$321K 0.09% 135
2022
Q3
$8.66M Buy
136,282
+8,055
+6% +$508K 0.07% 155
2022
Q2
$7.93M Sell
128,227
-6,450
-5% -$399K 0.06% 175
2022
Q1
$8.01M Buy
134,677
+5,200
+4% +$332K 0.05% 201
2021
Q4
$9.4M Buy
129,477
+7,593
+6% +$523K 0.06% 181
2021
Q3
$8.51M Buy
121,884
+17,429
+17% +$1.22M 0.06% 176
2021
Q2
$7.19M Buy
104,455
+3,249
+3% +$217K 0.05% 178
2021
Q1
$6.54M Buy
101,206
+8,037
+9% +$518K 0.05% 173
2020
Q4
$5.65M Buy
93,169
+4,021
+5% +$243K 0.04% 192
2020
Q3
$5.63M Buy
89,148
+4,451
+5% +$309K 0.05% 161
2020
Q2
$294K Hold
84,697
0.01% 679
2020
Q1
$6.33M Buy
84,697
+7,273
+9% +$503K 0.07% 139
2019
Q4
$5.03M Buy
77,424
+8,938
+13% +$582K 0.04% 195
2019
Q3
$4.34M Buy
68,486
+4,143
+6% +$271K 0.04% 208
2019
Q2
$4.35M Sell
64,343
-1,291
-2% -$84.9K 0.04% 210
2019
Q1
$4.27M Buy
65,634
+529
+0.8% +$35.2K 0.04% 203
2018
Q4
$4.07M Buy
65,105
+920
+1% +$64.3K 0.04% 212
2018
Q3
$4.96M Sell
64,185
-4,619
-7% -$349K 0.04% 218
2018
Q2
$4.87M Sell
68,804
-12,648
-16% -$893K 0.04% 235
2018
Q1
$6.7M Sell
81,452
-28,645
-26% -$2.28M 0.05% 188
2017
Q4
$7.89M Sell
110,097
-47,738
-30% -$3.63M 0.06% 178
2017
Q3
$12.8M Buy
157,835
+878
+0.6% +$67.1K 0.09% 104
2017
Q2
$11.1M Sell
156,957
-38,368
-20% -$2.55M 0.07% 111
2017
Q1
$13.3M Buy
195,325
+78,458
+67% +$5.52M 0.08% 104
2016
Q4
$8.37M Buy
116,867
+866
+0.7% +$64.4K 0.05% 115
2016
Q3
$9.18M Sell
116,001
-17,445
-13% -$1.42M 0.05% 114
2016
Q2
$11.1M Sell
133,446
-90,060
-40% -$7.99M 0.07% 96
2016
Q1
$20.5M Buy
223,506
+55,177
+33% +$4.98M 0.13% 63
2015
Q4
$17.1M Sell
168,329
-24,987
-13% -$2.6M 0.11% 67
2015
Q3
$19M Sell
193,316
-7,784
-4% -$865K 0.14% 65
2015
Q2
$23.5M Buy
201,100
+33,106
+20% +$3.62M 0.17% 63
2015
Q1
$16.5M Buy
167,994
+78,514
+88% +$7.97M 0.11% 73
2014
Q4
$8.49M Sell
89,480
-19,802
-18% -$2.05M 0.06% 107
2014
Q3
$11.6M Buy
109,282
+59,411
+119% +$5.82M 0.09% 84
2014
Q2
$4.13M Buy
49,871
+6,471
+15% +$504K 0.03% 166
2014
Q1
$3.08M Sell
43,400
-800
-2% -$62.7K 0.02% 196
2013
Q4
$3.32M Sell
44,200
-2,700
-6% -$188K 0.03% 167
2013
Q3
$2.95M Sell
46,900
-4,400
-9% -$263K 0.02% 176
2013
Q2
$2.63M Buy
+51,300
New +$2.67M 0.02% 202

Other funds holding GILD

Daiwa Securities Group's GILD Position: Q1 2026 in Review

Daiwa Securities Group increased its Gilead Sciences (GILD) stake by 1.9% in Q1 2026, buying an estimated $863K and bringing the position to 335,572 shares worth $46.8M. The position accounts for 0.13% of the portfolio, ranked #92.

Daiwa Securities Group first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Daiwa Securities Group held 335,572 shares of Gilead Sciences worth $46.8M as of Q1 2026.
  • Daiwa Securities Group bought 6,165 Gilead Sciences shares in Q1 2026, an estimated $863K.
  • Gilead Sciences made up 0.13% of Daiwa Securities Group's portfolio in Q1 2026, its #92 holding.
  • Daiwa Securities Group first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.